Articles tagged with Lung Cancer
Research presented at the ASTRO Annual Meeting has shown that short-term hormone therapy added to radiation increases survival for medium-risk prostate cancer patients, while a shorter radiation course is effective in reducing recurrence rates. Additionally, proton therapy reduces recurrences and is well-tolerated in prostate cancer pa...
Researchers at University Hospitals Case Medical Center found that African Americans with non-small cell lung cancer have a lower frequency of drug-sensitizing genetic mutations, which may impact response to EGFR inhibitor drugs. The study highlights the need for personalized treatment approaches based on ethnicity and genetic variation.
Research links CHRNA3 and CHRNA5 genes to increased lung cancer risk in African Americans, despite lower smoking rates. The study, published in Journal of Thoracic Oncology, confirms a stronger association with lung cancer risk than nicotine dependence.
A combination of PET/CT tests expedited diagnosis of lung cancer in a fast-tracked setting, demonstrating high sensitivity and accuracy. Researchers evaluated 114 patients and made accurate diagnoses for 92%, with malignancy detected in 84%. This approach allows for timely treatment initiation without delays.
A recent study confirms radon gas is the second leading cause of lung cancer, after smoking, in Spain and Romania. Radon levels were found to be a significant risk factor for lung cancer in homes, particularly in granite areas.
A University of Toronto-led nanomedicine research group has received a $5-million grant to develop technologies that allow for more selective detection of diseases, including lung and leukemia cancers. The team aims to speed up cancer diagnosis by incorporating plasmonics into existing procedures.
New research finds that adding cetuximab to chemotherapy reduces the risk of death from advanced non-small cell lung cancer by 13%, while also slowing disease progression and increasing the chance of tumor shrinkage. The study, which included over 2,000 patients, also found a 10% improvement in progression-free survival.
A large trial found that hormone replacement therapy (HRT) increases the risk of death from lung cancer, especially non-small-cell lung cancer. Women taking HRT were 71% more likely to die from lung cancer than those on placebo, with higher risks also seen in current and long-term past smokers.
A randomized phase III study found that pemetrexed significantly improved progression-free survival (4.3 months vs 2.6 months) and overall survival (13.4 months vs 10.6 months) compared to placebo in patients with advanced non-squamous NSCLC who did not progress after initial platinum-based chemotherapy.
Researchers at Johns Hopkins Medicine have identified unique characteristics of lung cancer in never-smokers, including exposure to second-hand smoke and radon gas. The guide recommends specific treatments, such as EGFR inhibitors, for patients with genetic mutations.
The report finds Hispanic/Latino Americans have a unique cancer risk profile, with lower incidence rates for all cancers combined, but higher rates of stomach, cervix, liver, and gallbladder cancers. They also experience later stage diagnoses for many cancers, including breast and melanoma.
Researchers found that primary lung cancer shifts to metastatic disease by suppressing microRNA-200, a family of small molecules that normally locks the tumor in a noninvasive state. Protecting miR-200 from blockade completely prevented metastasis in mice.
Researchers at the Mayo Clinic have discovered that the lung cancer oncogene PKCiota is necessary for the proliferation of lung cancer stem cells. The study found that an agent called aurothiomalate substantially inhibits growth of these cancer stem cells, suggesting a potential new treatment target.
Research published in the Journal of Thoracic Oncology found that narrow-band imaging bronchoscopy increases lung cancer detection specificity and can serve as an alternative method. The study confirms its efficiency by comparing it with white light and auto-fluorescence imaging.
A pooled analysis of six clinical trials found that pretreatment quality of life can predict overall survival in patients with advanced stage NSCLC. Patients with low self-assessed quality of life have twice the risk of death as those with high scores.
Researchers developed a gene assay that identifies key genes contributing to drug resistance in non-small cell lung cancer. The assay showed strong correlation between multi-gene signatures and individual chemotherapy agents, allowing for personalized treatment guidance.
The Tobacco Atlas estimates that tobacco use kills six million people annually, with two million cancer deaths projected by 2015. The global economy loses $500 billion due to tobacco use, mainly in low- and middle-income countries.
A recent study published in the Journal of Thoracic Oncology found that tumor size and level of visceral pleura invasion significantly impact the survival of non-small cell lung cancer (NSCLC) patients. Researchers analyzed data from over 9,700 surgical resection cases and divided patients into nine groups based on tumor size and VPI.
Researchers at the University of Pittsburgh School of Medicine have discovered a protein called cyclin B1 that is made in excess levels in many cancers. A vaccine targeting this protein may prevent malignancies in high-risk individuals, with promising results in mice vaccinated against it. The study's findings suggest that natural immu...
Researchers found that combination therapies tailored to patient prognosis improved patient outcomes and increased five-year, disease-free survival rates. Prophylactic cranial irradiation was shown to significantly decrease the risk for brain metastases in NSCLC patients.
A Montreal study links heavy consumption of beer and spirits to an increased risk of six different cancers, including oesophageal, colon, lung, pancreatic, liver, and prostate cancer. Heavy drinkers face a sevenfold increased risk of esophageal cancer and an 80% higher risk of colon cancer.
A combination of bevacizumab and erlotinib appears to be effective in treating non-small cell lung cancer (NSCLC) in elderly patients, with four partial responses observed. The regimen is well-tolerated, with common side effects including high blood pressure, fatigue, and diarrhea.
Researchers at Fox Chase Cancer Center have found that lung cancer patients who have progressed on a cetuximab-containing regimen may respond to erlotinib. The study suggests that patients who are no longer controlled by cetuximab can derive clinical benefit from erlotinib, offering an additional treatment option.
Researchers found that patients with second primary lung cancers (SPLC) are more likely to receive surgical treatment and have localized disease at diagnosis compared to those with one primary lung cancer (OPLC). However, SPLC patients experience a 12% higher lung cancer-specific mortality rate.
Studies presented at the WCLC confirm that targeted therapies have improved efficacy and prolonged progression-free survival time compared to chemotherapy. Patients with EGFR mutations who received gefitinib experienced longer progression-free survival and greater objective response rates, while erlotinib showed prolonged progression-f...
Fox Chase researchers found that DLX5 promotes cancer by activating the expression of MYC, a potent factor in numerous cancers. The discovery suggests that DLX5 could be an ideal target for future anti-cancer drugs.
Long-term adult cancer survivors face a higher risk of experiencing serious psychological distress due to effects on physical health and social adaptation. Approximately 5.6% of cancer survivors screened positive for severe psychological distress within the previous 30 days.
Researchers at Ohio State University Comprehensive Cancer Center identified a molecule, miR-21, playing an early and important role in the development of nonsmoking lung cancer. The study found that miR-21 levels were high in both early and late-stage tumors, suggesting it happens early in cancer development.
A new trial shows that chemotherapy plus radiotherapy, either with or without surgery, are viable options for patients with stage IIIA (N2) non-small-cell lung cancer. The treatment improved overall survival and progression-free survival rates compared to standard concurrent chemotherapy and radiotherapy alone.
A major study published in The Lancet found that surgery after chemotherapy and radiation can prolong survival without progression of the lung cancer, but does not improve overall survival compared to conventional treatment alone. Patients who underwent a section of the lung removal saw a major benefit from surgery.
UT Southwestern Medical Center researchers have received a $2 million grant to study lung cancer in nonsmokers. They will use a coordinated approach to discover biomarkers and develop a test to detect early-stage lung cancer.
A new study published in the International Journal of Cancer found that women who experienced non-natural menopause are at almost twice the risk of developing lung cancer compared to women who experienced natural menopause. The increased risk was particularly observed among women who had both their ovaries surgically removed.
Researchers found groundwater manganese positively associated with total cancer, colon cancer, and lung cancer death rates, while airborne manganese concentrations inversely associated with these cancers. Manganese exposure may worsen cancer rates due to increasing environmental levels.
Researchers found African Americans have lower survival rates for breast, prostate, and ovarian cancers due to biological factors, not socioeconomic ones. The study of 19,457 patients showed 49% more likelihood of death from early-stage breast cancer among African Americans.
Lung cancer's rapid spread is linked to a hyperactive WNT cell-signaling pathway, enabling aggressive tumor growth and poor clinical outcomes. The study identifies two genes activated by WNT that enhance invasion and reinitiation of tumor growth in other organs.
A study published in the Journal of Thoracic Oncology found a significant difference in the quality and type of lung cancer information available online in the US and Japan. The US websites were more likely to discuss standard treatment methods and had stricter ethical policies.
Researchers at UCLA's Jonsson Comprehensive Cancer Center have developed a unique model to isolate and study lung cancer stem cells. The model uses patient specimens and autologous tumor microenvironments to identify markers associated with cancer stem cells, providing proof-of-concept for the existence of these cells in lung cancer.
Researchers discovered that a nicotine receptor inhibitor, α-CbT, can double survival time in non-small cell lung carcinoma mice. The treatment showed significant antitumor activity by inducing apoptosis and had limited toxic effects on unaffected cells.
A new lung cancer therapy employing a vaporized viral vector to deliver a cancer-inhibiting molecule directly to lung tissue shows early promise in mouse trials. The delivery of genes via aerosol holds promise for the treatment of a broad spectrum of pulmonary disorders.
A study found that older age, lower education levels and longer smoking history are associated with a positive lung cancer diagnosis after an abnormal screening chest radiograph. A family history of lung cancer and suspicious masses also contribute to a true positive diagnosis.
A Phase III trial found that vandetanib significantly improved progression-free survival compared to chemotherapy alone. The therapy, which targets both EGFR and VEGFR, also showed reduced side effects, particularly nausea and vomiting.
A new study finds that exposure to particulate matter can reprogram genes associated with tumor suppression, affecting cancer development and outcomes. The changes are detectable after just three days of exposure, raising hopes for early interventions to prevent or reverse gene programming.
A Canadian Cancer Society-funded study will investigate the risk of bladder and kidney cancer associated with environmental exposure to arsenic in drinking water. Dr Louise Parker's three-year research project aims to help policy-makers decide whether new approaches to water testing and treatment are needed.
Researchers found that exercise programs significantly reduced lung cancer symptoms in patients who completed the study, with no deterioration in functional capacity or muscle strength. The study suggests that community-based or shorter exercise programs may be more feasible for lung cancer patients to complete.
A study found that patients diagnosed with lung cancer through CT scans had a significantly higher 5-year survival rate (91.2%) compared to those diagnosed with x-rays (77.8%). The study suggests that early detection of the disease using CT scans improves patient prognosis.
Researchers are launching a multi-institutional effort to develop a test to detect early-stage lung cancer in lifetime nonsmokers. The project aims to create a better understanding of the biology of lung cancer and identify potential biomarkers.
Researchers discuss personalized treatment options for early-stage lung cancer, using targeted therapies and cancer vaccines. A gene signature is being used to predict which patients will benefit from an immune-boosting vaccine designed to target MAGE-A3 protein.
Researchers found women tend to be younger when developing lung cancer, despite smoking less than men, increasing the risk of tobacco carcinogens. Women's awareness of other cancers like breast cancer may also contribute to their vulnerability, with median survival after surgery being longer for women.
Researchers present new techniques for early diagnosis and treatment of lung cancer, improving 5-year survival rates from 10% to 70%. A new factor that correlates with clinical parameters may also help indicate patient prognosis.
A phase III study found that adding cetuximab to standard chemotherapy for non-small-cell lung cancer (NSCLC) extends survival by almost one month compared to chemotherapy alone. The treatment has been shown to target epidermal growth factor receptor, which plays a key role in tumour growth.
A large prospective case-cohort study found no association between dietary acrylamide intake and lung cancer risk in men, but suggested an inverse association in women. The researchers hypothesize that acrylamide may affect hormonal balances to explain the findings.
Researchers are exploring new treatments for lung cancer using targeted therapies and personalized care. Studies have shown promising results in improving patient outcomes, including the use of molecular targeted therapies and chemotherapy combinations.
A new report reveals a significant increase in the number of people diagnosed with cancer in Ireland, but also shows that survival rates are rising for certain types of cancer. The report highlights the importance of prevention and early detection in reducing the burden of cancer.
Notch1 contributes to lung fibrosis by increasing myofibroblasts, while SOCS-1 inhibits prostate cancer growth. TIP30 prevents lung cancer metastasis, and SPARC accelerates kidney disease progression. These findings highlight potential new therapeutic targets.
A computer-aided detection system has been shown to detect 45-55% of overlooked lung cancer nodules, potentially leading to earlier diagnosis and improved survival rates. The study suggests that CAD software can assist radiologists in identifying subtle signs of early lung cancer.
Researchers at Washington University School of Medicine have uncovered the genetic source of pleuropulmonary blastoma (PPB), a rare and aggressive childhood lung cancer. The study found that some children with PPB are born with deleterious mutations in the DICER1 gene, which is involved in regulating gene expression.
Human lung tumors can destroy Vitamin D, a hormone with anti-cancer properties, according to a new study. The researchers developed a test to measure Vitamin D levels in tissues and blood, which could help identify the best approaches to maintain therapeutic levels of Vitamin D.
Researchers found that a urine metabolite called NNAL predicts risk of lung cancer in smokers, with higher levels associated with increased risk. The study, published by the American Association for Cancer Research, analyzed data from over 50,000 patients.
Scientists at the University of Cincinnati have identified the RGS17 gene as a major suspect in familial lung cancers. Further investigation may lead to genetic testing for high-risk patients, enabling early detection and treatment.
A study found that black patients with non-small cell lung cancer are 37% less likely to receive recommended surgery and 42% less likely to receive recommended chemotherapy than white patients. The disparity remains despite efforts to address inequalities in medical treatment.